CRISPR Therapeutics: Gene Editing Company Profile and Pipeline 2026

CRISPR Therapeutics is the company that turned a Nobel Prize-winning scientific discovery into the first approved CRISPR gene editing therapy. While dozens of biotech firms are working on gene editing, CRISPR Therapeutics holds a singular distinction: it brought Casgevy to market, proving that CRISPR-Cas9 can clear the highest regulatory bars in the world and reach real patients. But a single approved product does not define a company's future. What matters now is whether CRISPR Therapeutics can build on that foundation with a pipeline that justifies its valuation and competitive position.

This profile examines the company's history, technology, pipeline, finances, and competitive standing as of early 2026.

What Is CRISPR Therapeutics?

CRISPR Therapeutics AG (NASDAQ: CRSP) is a gene editing biopharmaceutical company focused on developing transformative therapies for serious diseases. The company was co-founded in 2013 by Emmanuelle Charpentier, who shared the 2020 Nobel Prize in Chemistry with Jennifer Doudna for their pioneering work on the CRISPR-Cas9 gene editing system. Charpentier's foundational research at the University of Vienna and Umea University established the molecular mechanism that made programmable genome editing possible.

The company is legally headquartered in Zug, Switzerland, with its primary operational and research headquarters in Boston, Massachusetts. It also maintains research facilities in Cambridge, Massachusetts, and has a growing global footprint tied to its clinical and commercial operations.

CRISPR Therapeutics trades on the NASDAQ under the ticker CRSP and carries a multi-billion dollar market capitalization. The company went public in 2016 and has been one of the most closely followed gene editing stocks since, alongside Intellia Therapeutics and Editas Medicine, the other two companies often referred to as the "Big Three" of CRISPR.

CEO Samarth Kulkarni has led the company since 2017, guiding its transition from preclinical startup to commercial-stage biopharma. Charpentier, while no longer involved in daily operations, remains central to the company's scientific identity.

How Does Casgevy Work?

Casgevy (exagamglogene autotemcel) is the therapy that put CRISPR Therapeutics on the map. Developed in partnership with Vertex Pharmaceuticals, it received approval from the UK's MHRA in November 2023, followed by the European Medicines Agency and the U.S. FDA in December 2023. These approvals covered two indications: sickle cell disease (SCD) in patients with recurrent vaso-occlusive crises and transfusion-dependent beta-thalassemia (TDT).

The therapy uses an ex vivo approach. A patient's own hematopoietic stem cells are collected, edited in a laboratory using CRISPR-Cas9, and then infused back into the patient after myeloablative conditioning with busulfan chemotherapy.

The specific editing target is the BCL11A gene, which acts as a molecular switch that silences fetal hemoglobin (HbF) production after birth. By disrupting BCL11A in the patient's stem cells, Casgevy reactivates the production of fetal hemoglobin. This form of hemoglobin functions effectively for oxygen transport and, critically, does not cause the red blood cell sickling that defines SCD nor the hemoglobin deficiency at the core of TDT.

The scientific elegance is worth noting: rather than correcting the sickle cell mutation directly, Casgevy turns on a backup hemoglobin system that humans already possess during fetal development.

Clinical Results

The pivotal trial data were strong. In sickle cell disease, 29 of 31 evaluable patients (93.5%) achieved freedom from vaso-occlusive crises for at least 12 consecutive months. In beta-thalassemia, 28 of 32 evaluable patients achieved transfusion independence for at least 12 months. Patients demonstrated sustained fetal hemoglobin levels typically exceeding 40% of total hemoglobin, and follow-up data through 2025 continued to show durability.

Commercial Rollout and Challenges

Casgevy carries a list price of approximately $2.2 million for a one-time treatment. Vertex Pharmaceuticals has argued that this reflects the curative potential of the therapy relative to the estimated lifetime cost of managing these diseases, which can range from $1.6 million to $6 million per patient. For a deeper look at how gene therapy pricing works, see our gene therapy cost guide.

However, commercialization has faced several real-world challenges:

Treatment complexity. The full Casgevy treatment journey spans several months, including cell collection, manufacturing, chemotherapy conditioning, infusion, and recovery. This is not a simple injection.
Center capacity. Only qualified treatment centers with stem cell transplant expertise can administer the therapy. The number of authorized centers has been growing, but geographic access remains uneven.
Payer negotiations. In the United States, a significant proportion of sickle cell patients are covered by Medicaid. State Medicaid programs face budget constraints in covering therapies at this price point. Outcomes-based contracts have been one approach to addressing payer concerns.
Patient throughput. Manufacturing is patient-specific, meaning each treatment is essentially a custom product. Scaling production while maintaining quality has been an ongoing focus.
Global access. Sickle cell disease disproportionately affects populations in sub-Saharan Africa, where the current treatment model is not economically viable. The access crisis surrounding Casgevy remains one of the most important ethical questions in gene therapy.

Despite these challenges, the commercial rollout has been progressing. Vertex reported increasing patient starts through 2025, with the trajectory suggesting growing but still modest revenue relative to the total addressable patient population.

Pipeline Beyond Casgevy

CRISPR Therapeutics has been deliberate about building a pipeline that extends well beyond hemoglobinopathies. The company's programs fall into three strategic areas: immuno-oncology, in vivo gene editing, and regenerative medicine.

Allogeneic CAR-T Cell Therapies (Immuno-Oncology)

Current approved CAR-T therapies are autologous -- manufactured from each patient's own T cells -- making them expensive, slow, and sometimes unfeasible. CRISPR Therapeutics is using gene editing to create CAR-T cells from healthy donor T cells, making multiple edits to prevent graft-versus-host disease and immune rejection. The key programs include:

CTX110 — targeting CD19-positive B-cell malignancies, including non-Hodgkin lymphoma and B-cell acute lymphoblastic leukemia. This program has generated clinical data showing anti-tumor activity, though the competitive landscape in CD19-targeted therapies is crowded.
CTX130 — targeting CD70-positive cancers, including renal cell carcinoma and T-cell lymphoma. CD70 is an interesting target because it is expressed on certain solid tumors and hematologic malignancies, giving the program broader potential reach.

The allogeneic approach, if successful, could fundamentally change the CAR-T market by reducing manufacturing timelines from weeks to days and lowering costs. However, durability of response remains a key question, as allogeneic cells may be cleared by the patient's immune system faster than autologous cells. For more context on the off-the-shelf cell therapy landscape, see our article on CRISPR companies to watch.

In Vivo Gene Editing Programs

CRISPR Therapeutics has been expanding into in vivo gene editing, where therapeutic editing components are delivered directly into the body rather than editing cells outside the body. This represents the next frontier for the company and for the gene editing field broadly.

The company has disclosed programs targeting:

Cardiovascular disease — focusing on liver-directed editing approaches for conditions related to lipid metabolism. This puts CRISPR Therapeutics in a space currently led by Verve Therapeutics, which is pursuing base editing to lower cholesterol.
Autoimmune diseases — exploring editing strategies that could modulate the immune system to treat conditions like type 1 diabetes and inflammatory disorders.

In vivo editing requires solving the delivery challenge -- getting CRISPR components into the right cells at sufficient efficiency. CRISPR Therapeutics has been developing lipid nanoparticle (LNP) delivery systems for this purpose. This area is less mature than the ex vivo programs but represents the long-term growth strategy.

Regenerative Medicine

CRISPR Therapeutics has a collaboration with ViaCyte (now part of Vertex) focused on creating gene-edited, immune-evasive stem cell-derived beta cells for type 1 diabetes. The program is still in early clinical development, but if successful, it could offer a functional cure by eliminating the need for both insulin injections and immunosuppressive drugs.

Technology Platform

CRISPR Therapeutics' platform is built on the CRISPR-Cas9 system, which uses a guide RNA to direct the Cas9 enzyme to a specific genomic location where it makes a double-strand break. The cell's natural DNA repair mechanisms then introduce the desired change. The advantages are well-established: CRISPR-Cas9 is programmable, efficient, and has the longest clinical track record of any gene editing technology.

Limitations and the Competitive Technology Landscape

However, CRISPR-Cas9 also has known limitations that competitors are working to address:

Double-strand breaks. Traditional CRISPR-Cas9 creates double-strand breaks in DNA, which carry a risk of unintended insertions, deletions, or chromosomal rearrangements. Newer approaches like base editing and prime editing make precise changes without cutting both DNA strands, potentially offering a better safety profile for certain applications.
Off-target editing. While engineering improvements have significantly reduced off-target effects, the possibility remains a concern, particularly for in vivo applications where edited cells cannot be screened before returning them to the patient.
Delivery constraints. The Cas9 protein is relatively large, which can complicate delivery, especially for in vivo applications using viral vectors like AAV. Smaller Cas enzymes and non-viral delivery systems are areas of active development industry-wide.

CRISPR Therapeutics has been investing in next-generation editing capabilities, including enhanced specificity Cas9 variants and exploring complementary editing modalities. The company's long-term competitiveness will depend in part on whether it can evolve its platform to keep pace with innovations from competitors. For a comparison of next-generation editing approaches, see Intellia vs Beam vs Prime.

Intellectual Property Position

CRISPR Therapeutics holds exclusive licenses to key CRISPR-Cas9 patents for therapeutic applications derived from Charpentier's foundational work. The CRISPR patent landscape remains complex, with overlapping claims among the Broad Institute (licensing to Editas Medicine) and UC Berkeley (associated with Intellia Therapeutics). However, cross-licensing agreements and technology diversification have reduced the existential risk that characterized the early CRISPR patent wars.

Financial Position

CRISPR Therapeutics is in the early stages of generating product revenue through its share of Casgevy profits. Vertex Pharmaceuticals leads commercialization, with CRISPR Therapeutics receiving profit-sharing payments under their collaboration agreement. Revenue has been growing as patient starts increase, but the ramp has been gradual given treatment complexity.

The company maintains significant cash reserves, providing runway to fund operations and pipeline advancement for several years and reducing near-term dilution risk. R&D spending has grown as the allogeneic CAR-T programs and in vivo editing platform advance into clinical stages.

The Vertex Partnership

The Vertex collaboration has been central to CRISPR Therapeutics' success. Vertex brought clinical development and commercial capabilities that CRISPR Therapeutics could not have replicated alone. This de-risked Casgevy's launch but means the company receives only a portion of the economics from its most validated product. The ability to advance pipeline programs independently will be important for long-term value creation.

Competitive Landscape

CRISPR Therapeutics operates in an increasingly competitive gene editing landscape. Understanding where it fits relative to peers is essential for evaluating the company.

Intellia Therapeutics (NTLA) has positioned itself as the leader in in vivo CRISPR editing, with its NTLA-2001 program for transthyretin amyloidosis showing strong clinical data. While CRISPR Therapeutics has the first approved product, Intellia may have the more transformative platform for in vivo applications. The two companies are likely to compete directly as CRISPR Therapeutics expands its own in vivo programs.

Beam Therapeutics (BEAM) uses base editing technology, making precise single-base changes without double-strand breaks. Beam's sickle cell program (BEAM-101) puts it in direct competition with Casgevy, though with a potentially differentiated safety profile.

Editas Medicine (EDIT) was historically a direct peer as one of the original "Big Three," but has undergone strategic shifts and leadership changes that have weakened its competitive position. Editas retains access to Broad Institute IP and has differentiated in vivo ocular editing programs.

Prime Medicine (PRME) is developing prime editing, capable of making all 12 types of point mutations plus small insertions and deletions. Earlier stage but a potential long-term threat if delivery challenges are solved.

For a detailed head-to-head comparison, see our comparison of Intellia, Beam, and Prime Medicine.

CRISPR Therapeutics' primary competitive advantage is straightforward: it has an approved, revenue-generating product. In biotech, the distance between clinical data and commercial approval is enormous. Having crossed that threshold gives the company credibility with regulators, payers, and investors that competitors are still working to establish.

Investment Considerations

Disclaimer: This section is for informational and educational purposes only. It does not constitute investment advice. Gene editing stocks are volatile and carry significant risk. Consult a qualified financial advisor before making any investment decisions.

The Bull Case

First-mover advantage. Casgevy's approval provides a commercial foundation that no other pure-play CRISPR company has. Revenue is real, growing, and backed by a proven therapy.
Pipeline optionality. The allogeneic CAR-T, in vivo editing, and regenerative medicine programs provide multiple shots on goal across large therapeutic markets.
Strong partnership. The Vertex collaboration de-risks Casgevy commercialization and brings world-class drug development expertise.
Cash position. Significant reserves reduce near-term financing risk and provide time to advance the pipeline.
Expanding addressable market. As authorized treatment centers grow and manufacturing scales, Casgevy's commercial potential increases.

The Bear Case

Casgevy revenue ramp is slow. The complexity of the treatment process limits patient throughput. Revenue growth may disappoint relative to the theoretical market size.
Technology risk. CRISPR-Cas9 may be superseded by safer or more precise editing technologies like base editing or prime editing for certain indications.
Competition in CAR-T. The allogeneic CAR-T space is crowded, and durability of response remains unproven relative to autologous approaches.
In vivo programs are early. CRISPR Therapeutics is behind Intellia in the in vivo gene editing race, and catching up will require significant time and investment.
Shared economics. The Vertex partnership, while beneficial for execution, means CRISPR Therapeutics only receives a portion of Casgevy revenue.

Key Catalysts in 2026

Several events could meaningfully move the stock in 2026:

Casgevy commercial data. Quarterly revenue reports and patient start disclosures will signal whether the commercial ramp is accelerating.
CTX110/CTX130 clinical updates. Data readouts from the allogeneic CAR-T programs will be critical for validating the next major pipeline pillar.
In vivo program milestones. IND filings or early clinical data from in vivo editing programs would signal pipeline expansion into higher-growth areas.
Competitive developments. Approvals or clinical failures from competitors could reshape the relative positioning of the entire sector.
Regulatory developments. Any expansion of Casgevy's label to additional indications or age groups would expand the addressable market.

The Bottom Line

CRISPR Therapeutics occupies a unique position in the gene editing landscape: it is the only company that has taken a CRISPR-based therapy from laboratory discovery through regulatory approval to commercial launch. That accomplishment is not trivial. It required navigating scientific, manufacturing, regulatory, and commercial challenges that many of its competitors have yet to face.

But the company's future depends on more than Casgevy. The slow revenue ramp and access barriers mean that Casgevy alone may not justify a premium valuation. The allogeneic CAR-T programs and in vivo editing pipeline represent the growth story, and the key question is whether those programs will deliver. CRISPR Therapeutics has proven it can execute at the highest level. Whether it can do so repeatedly, across multiple therapeutic areas, is what will define its next chapter.

For broader context on the gene editing company landscape, see our overview of CRISPR companies to watch in 2026.

Sources & Further Reading

FDA Casgevy Approval Announcement, December 8, 2023 — FDA Press Release.
Frangoul, H. et al. "CRISPR-Cas9 Gene Editing for Sickle Cell Disease and Beta-Thalassemia." New England Journal of Medicine 384, 252-260 (2021).
CRISPR Therapeutics corporate pipeline and investor presentations, 2025-2026 — crispr.com.
Charpentier, E. & Doudna, J. "The New Frontier of Genome Engineering with CRISPR-Cas9." Science 346, 1258096 (2014).
Vertex Pharmaceuticals Casgevy commercial updates, earnings calls 2024-2025.

Last updated: April 2026.